Comprehensive population pharmacokinetic modelling of sugemalimab, an anti‐programmed death‐ligand 1 (PD‐L1) human monoclonal antibody, in patients with solid tumours or lymphomas across multiple Phase I–III studies
Year: 2024
Type: article
DOI: 10.1111/bcp.16276
Authors: Kun Wang, Chaohsuan Pan, Fengyan Xu, Archie N. Tse, Yucheng Sheng
Institution: CStone Pharmaceuticals (China)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4403289092